Harvard-incubated, protein-targeting startup emerges from stealth with $80M

With technology licensed from Harvard Medical School and $80 million to get its lead candidate into the clinic, a Harvard-incubated startup is looking to break new ground. Tectonic Therapeutic, which emerged from stealth on Thursday, is planning on developing drugs targeting novel G-protein-coupled receptors, or GPCRs, a class of cell surface receptors involved in a wide range of bodily functions.